Date
- Thursday, 22 January 2009, All day
Location
- European Medicines Agency, Amsterdam, the Netherlands
Discussion with invited stakeholders to express their initial thoughts and provide feedback on their understanding and expectations on the level of transparency of EMEA activities.
Documents
Agenda - Workshop on the EMEA transparency policy
English (EN) (78.81 KB - PDF)
Workshop on the EMEA transparency policy - List of participants
English (EN) (100.99 KB - PDF)
Report on workshop on the development of an EMEA transparency policy
English (EN) (289.95 KB - PDF)
Overview current EMEA transparency measures
English (EN) (357.47 KB - PDF)
Workshop on the development of an EMEA transparency policy
English (EN) (1.26 MB - PDF)
Discussion on the EMEA transparency policy - Perspectives from Healthcare Professionals
English (EN) (1.16 MB - PDF)
Pharmaceutical Industry views
English (EN) (32.44 KB - PDF)
IFAH-Europe views
English (EN) (686.16 KB - PDF)
Workshop on the development of an EMEA transparency policy - Draft key principles
English (EN) (516.95 KB - PDF)
Commercial confidential information - Principles to be considered
English (EN) (367.81 KB - PDF)
Transparency at the MEB: a necessity
English (EN) (187.28 KB - PDF)
Key messages in relation to the importance of commercially confidential information
English (EN) (104.19 KB - PDF)
Presentation given by The Association of the European Self-Medication Industry (AESGP)
English (EN) (1.15 MB - PDF)
Transparency and commercially confidential information - EGA’s perspective
English (EN) (462.2 KB - PDF)